Stayble Therapeutics announced that the drug candidate STA363 had not met the primary endpoint in the phase IIb study in patients with degenerative disc disease. Now, however, additional analyses from the study are presented that may prove to have a bearing on the company's other project regarding herniated discs.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.2375 SEK | -0.63% | -13.79% | -21.62% |
1st Jan change | Capi. | |
---|---|---|
-21.62% | 699K | |
+5.33% | 111B | |
+12.11% | 105B | |
-12.56% | 22.34B | |
-3.70% | 21.93B | |
-6.03% | 18.59B | |
-35.21% | 18.12B | |
-10.86% | 16.96B | |
+5.10% | 13.7B | |
+37.57% | 12.45B |
- Stock Market
- Equities
- STABL Stock
- News Stayble Therapeutics AB
- Stayble Therapeutics Announces New Analyses of Phase IIb Study Strengthen Disc Herniation Project